Sierra Summit Advisors LLC Purchases New Position in Novo Nordisk A/S $NVO

Key Points

• Sierra Summit Advisors LLC initiated a new position in Novo Nordisk in the fourth quarter, buying 208,905 shares valued at about $10.6 million. The stake represents roughly 1.6% of the firm’s portfolio.
• Institutional ownership remains meaningful, with several other investors also adding to their Novo Nordisk holdings, while institutions overall own 11.54% of the stock.
• Analysts have grown more cautious on NVO: recent rating changes and target cuts leave the stock with a Hold consensus and an average price target of $65.56. Meanwhile, the company faces both encouraging obesity-drug data and intensifying competition from rivals like Eli Lilly and Viking Therapeutics.

Sierra Summit Advisors LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 208,905 shares of the company's stock, valued at approximately $10,629,000. Novo Nordisk A/S comprises about 1.6% of Sierra Summit Advisors LLC's portfolio, making the stock its 23rd largest holding.

A number of other institutional investors have also recently made changes to their positions in the business. Quotient Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company's stock valued at $463,000 after acquiring an additional 177 shares during the last quarter. Certuity LLC lifted its holdings in shares of Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company's stock valued at $257,000 after acquiring an additional 177 shares during the last quarter. Oakworth Capital Inc. lifted its holdings in shares of Novo Nordisk A/S by 41.6% in the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company's stock valued at $31,000 after acquiring an additional 182 shares during the last quarter. True North Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company's stock valued at $270,000 after acquiring an additional 199 shares during the last quarter. Finally, Joel Isaacson & Co. LLC lifted its holdings in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company's stock valued at $1,170,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on NVO shares. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a "peer perform" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
• Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk CPSE: NOVO B Has Changed Its Investment Story
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
• Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
• Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential
• Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook (NVO)
• Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $45.07 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a market capitalization of $201.23 billion, a P/E ratio of 10.58, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The company's 50-day moving average is $40.05 and its 200 day moving average is $46.51.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.47 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.